PTCT

PTCT PTC Therapeutics, Inc.

PTC Therapeutics, Inc. · NASDAQ
Market Closed
56.42
▼ ⁦-3.27%⁩ (-1.91)
Post-market56.99+1.01% (+0.57)
Market Cap$4.7B
Beta0.55
52w Low52w High
56.1890.87
Last Week
⁦-11.14%⁩
Last Month
⁦-10.50%⁩
Last 3 Months
⁦-20.60%⁩
Last Year
⁦-23.57%⁩
Open on chart
Premium content
Fair Value
Current price⁦$56⁩
  • Analyst targetsLow confidence
    6 analysts
    ⁦$104⁩
    ⁦+84%⁩
    Range ⁦⁦$75⁩–⁦$137⁩⁩Typical for this method across large companies: ⁦+20%⁩
  • Value at the industry multiple
    Next year's earnings × ⁦19.9⁩, median of 62 companies
    ⁦$37⁩
    ⁦−34%⁩
    Range ⁦⁦$21⁩–⁦$75⁩⁩
  • Discounted cash flow modelLow confidence
    ⁦8.6%⁩ discount rate · ⁦9%⁩ growth a year
    ⁦$20⁩
    ⁦−65%⁩
    Range ⁦⁦$20⁩–⁦$20⁩⁩Typical for this method across large companies: ⁦−39%⁩

The floor: what the company is worth if growth stopped today

  • Value with no growth
    Today's after-tax operating profit, held flat forever, at a ⁦8.6%⁩ discount rate
    ⁦$35⁩
    ⁦−38%⁩

⁦38%⁩ of today's price is what a buyer pays for growth that has not happened yet.

1
methods value it above the price
0
methods near the price
2
methods value it below the price

10-year US Treasury yield ⁦5.04%⁩ as of ⁦2026-11-19⁩. Estimates computed from company data and analyst targets, not investment advice.

Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$700 / yr
Monthly plan
$99 / mo
Analyst Estimates

The company reports in USD. Forecast amounts use the data provider’s units.

Quarterly estimates

Fiscal period end

Last refreshed

EPS Estimate
0.3468
Range -1.3558 – 1.8918
Analysts 3
Revenue Estimate
330.38M
Range 309.5M – 349.54M
Analysts 8
Fiscal period end

Last refreshed

EPS Estimate
0.4589
Range 0.269 – 0.6487
Analysts 4
Revenue Estimate
312.36M
Range 290.83M – 333.88M
Analysts 3
Fiscal period end

Last refreshed

EPS Estimate
0.5434
Range 0.4933 – 0.5908
Analysts 1
Revenue Estimate
332.96M
Range 309.35M – 355.31M
Analysts 1
Fiscal period end

Last refreshed

EPS Estimate
0.534
Range 0.4848 – 0.5806
Analysts 1
Revenue Estimate
343.66M
Range 319.29M – 366.73M
Analysts 1

Annual estimates

Fiscal period end

Last refreshed

EPS Estimate
0.5261
Range -0.3156 – 0.9995
Analysts 7
Revenue Estimate
1.32B
Range 1.3B – 1.34B
Analysts 10
Fiscal period end

Last refreshed

EPS Estimate
2.7301
Range 1.4163 – 4.2396
Analysts 7
Revenue Estimate
1.43B
Range 1.33B – 1.56B
Analysts 10
Fiscal period end

Last refreshed

EPS Estimate
4.3808
Range 1.4786 – 8.8848
Analysts 11
Revenue Estimate
1.63B
Range 1.3B – 2.05B
Analysts 12
3 analysts
Premium content
Which listings have analyst coverage?

EL7 refreshes analyst ratings and price targets for active company listings on Nasdaq, the New York Stock Exchange and NYSE American, including US-listed depositary receipts. Funds (including ETFs and mutual funds), OTC listings and listings on other exchanges are outside this coverage. Some eligible listings may have no published target or analyst call in the past 12 months.

EL7 checks for new ratings several times on weekdays, refreshes consensus targets on weekdays and updates monthly rating history once a month.

Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
  • P/E (TTM)
    —
    —
  • Forward P/E
    29.96x
    4.63x37.03x
    Near median
  • EV / EBITDA
    15.42x
    3.71x29.64x
    Cheap
  • FCF Yield
    0.0%
    -99.3%7.8%
    Strong
  • Revenue Growth YoY
    -35.1%
    -48.8%73.2%
    Below average
  • EPS Growth YoY
    -116.4%
    -103.1%98.8%
    Weak
  • Gross Margin
    92.4%
    15.1%89.4%
    Exceptional
  • ROIC
    37.3%
    -150.5%16.1%
    Exceptional
  • Net Debt / EBITDA
    -7.16x
    0.00x1.99x
    Net cash
  • Dividend Yield
    Pays no dividend
    —
  • Payout Ratio
    Pays no dividend
    —
  • Altman Z-Score
    0.72
    -17.7515.77
    Above average
Financial Analysis
Related News

Frequently Asked Questions

What is PTC Therapeutics, Inc. stock?▼

PTC Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in PTC Therapeutics, Inc.?▼

You can buy PTC Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating PTC Therapeutics, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does PTC Therapeutics, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in PTC Therapeutics, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.